JINDAL DRILLING & INDUSTRIES LTD.

INTERIM CORPORATE OFFICE: PLOT NO.106, SECTOR-44, GURGAON-122 002 HARYANA (INDIA)

TEL: +91-124-4624000, 2574326, 2575626 • FAX: +91-124-2574327

E-mail: contacts@jindaldrilling.in Website: www.jindal.com

CIN: L27201MH1983PLC233813

CORPORATE OFFICE: PLOT NO. 30, INSTITUTIONAL SECTOR-44, GURGAON-122 002 HARYANA (INDIA)

JDIL/SECT/SE/2022-23

January 25, 2023

BSE Ltd

25th Floor, P.J. Towers, Dalal Street, Mumbai-400 001 Security Code: 511034 **National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block-G Bandra-Kurla Complex Bandra (E), Mumbai – 400 051

Security Code: JINDRILL

Sub: Newspaper advertisement in respect of Published Financial Results for the Quarter and nine months ended December 31, 2022.

Dear Sir/Madam,

Pursuant to Regulation 47 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find enclosed herewith the copy of un-audited financial results for the quarter and nine months ended December 31, 2022 as published by the Company in Newspapers viz. Business Standard (In English) and Navshakti (in Marathi) on January 24, 2023.

You are requested to kindly take the same on record.

Yours faithfully,


For Jindal Drilling and Industries Limited

(Saurabh Agrawal)
Company Secretary

Encl.: As above







TEL: +91-02194-238511, 238512, 238567, 238569 • FAX: +91-02194-238513

MEMBER: INTERNATIONAL ASSOCIATION OF DRILLING CONTRACTORS, HOUSTON, TEXAS, USA





KERALA WATER AUTHORITY

<u>e-Tender Notice</u>
Tender No : T No. 91 & 92/2022-23/SE/Q Stateplan- constuction of recycling plant at Sathamcotta, AMRUT-New water connection a Sakthikulangara and Thrikkadavoor area under Kollam Corporation.

EMD: Rs. 1,00,000/-. Tender fee: Rs. 8270+1489(18% GST-It will be paid by the contractor on reverse charge basis while filing his returns)

Last Date for submitting Tender: 06.02.2023 02:00 pm

www.etenders.kerala.gov.in Phone: 04742745293, Website: www.kwa.kerala.gov.in

KWA-JB-GL-6-1487-2022-23



Express Highway, Santacruz (East), Mumbai - 400 055. Corporate Identity Number: L24100MH1983PLC029442 Tel: (91-22) 6640 2323 Email: info@lupin.com Website: www.lupin.com

PUBLIC NOTICE

This is to Notify to all our trade stockiest / wholesalers / retailers / consumer and Public at large that LUPIN LIMITED has reduced the Maximum Retail Prices (MRPs) in respect of the following Scheduled formulations in accordance with the Ceiling Price notified by NPPA Vide SO No. 5938(E) & 5939(E) dated 19th Dec 2022, 87(E), 88(E) & 89(E)

Code	or company's Depot/C&F. Product Name	Pack Size	MRP Per	MRP Pe Strip/Via
414384		10 X 15T	Pack 2,891.00	Amp 289.1
404221	TONACT 10 10X15T	10 X 15T	740.50	74.0
	TONACT 20 10X15T	10 X 15T	1,881.50	188.1
	TONACT 80 10X10 T EPILIVE 500 10X15 T	10 x 10 T 10 X 15T	4,053.20 1,945.00	405.3 194.5
	TELISTA 40 10 X 15 T	10 X 15T	1,013.00	101.3
407823		10 X 15T	875.00	87.5
417842	\ /		1,995.00	99.7
	GLUCONORM SR 10X15 T RAMISTAR 5 (10X15) T	10 X 15T 10 X 15T	302.00 1,226.40	30.2 122.6
	L-CIN 500 10 X 10 T	10 x 10 T	898.00	89.8
	RAMISTAR 2.5 (10X15) T	10 X 15T	781.20	78.
	STARPRESS XL 25 10X15 T TELEKAST 10 10X10T	10 X 15T 10 x 10 T	630.00 1,641.90	63.0 164.1
400684		10 x 10 T	446.80	44.6
508398		20 ml	54,662.70	54,662.7
417574	LYOPHILLIZED POWDER LNZ 600 TAB (10X10 T)	10 x 10 T	3,562.70	356.2
	DUET 625 (10X10T)	10 x 10 T	1,827.50	182.7
	STALOPAM 10 (10 X 2 X 10T)	10 x2 x10 T	1,798.00	89.9
406273		10 X 15T	606.50	60.6
502062 403818	TAZAR INJ 2.25 GM (5X1V) EPILIVE 750 10X10T	5x1 V 10 x 10 T	956.50 1,932.00	191.3 193.2
411555	TELEKAST 5 CHEWABLE TABLETS	10 x 10 T	1,170.40	117.0
500004	BP (10X10T)	10 v 10 T	1 007 50	400
508061 503786	CLAVIDUR 625 TAB 10X10T CETIL DRY SYRUP	10 x 10 T 30 ml	1,827.50 158.25	182.7 158.2
408237	TELISTA 20 10 X 15 T	10 X 15T	581.00	58.
411554	TELEKAST 4 CHEWABLE TABLETS	10 x 10 T	1,002.40	100.2
415209	BP (10X10T) GLADOR 2 (10 X 15 T)	10 X 15T	868.50	86.8
408239	TELISTA 80 10 X 15 T	10 X 15T	1,559.00	155.9
411260	COMBUTOL 800 (30 X 10T) BLISTER PACK	30x10 T	1,392.00	46.4
414954		10 X 15T	944.00	94.4
400444	CYCLORIN 250MG 10X6C	10 x 6 C	3,547.40	354.
	STALOPAM 5 (10 X 2 X 10T)	10 x2 x10 T	1,003.00	50.
	NITROBEST (10 X 10 TAB) L-CIN 750 10 X 10 T	10 x 10 T 10 x 10 T	791.50 1,243.00	79.1 124.3
	CZ-3 TABS 10X5X10T	10 X 10 T	940.00	
404551	L-CIN 250 10 X 10 T	10 x 10 T	481.50	48.
	GLADOR 1 (10 X 15 T)	10 X 15T	554.00	
	PYZINA 750 12X10T STALOPAM 20 10X10T	12 x 10 T 10 x 10 T	864.00 1,434.50	
400111	R-CIN 450 5X2X10C	5x2x10 C	566.50	
403348	STARPRESS XL 100 (10X10T)	10 x 10 T	1,497.00	149.
	LUPIFLO 15 (1 X 10 VIAL)	1 X 10 V	18,751.50	
	COMBUTOL 600 12X10T EPILIVE SYRUP 100ML	12 x 10 T 100 ML	458.40 396.45	38.2 396.4
502699	TAZAR INJ 1.125 GM (10X1V)	10 x 1 Single	995.00	99.
	THYROUP 50 (1X120 T)	120 T	123.64	123.6
	M CIN 20X5T KRONOSTAR 300MG 10 X 10 TAB	20X5 T 10 x 10 T	2,579.00 445.70	
	THYROUP 25 (1X120 T)	120 T	173.37	173.3
402661	PYZINA 1000 12X10T	12 x 10 T	1,261.80	105.
	ETHIDE TABLETS 10 X 6T	10X6T	887.70 50.40	
	PROTERA - IV VIALS (1V) R-CIN 300 5X2X10C	1 V 5x2x10 C	50.40 460.00	
510831	CETIL DRY SYRUP 60ML	60 ML	316.51	316.
	COMBUTOL 400 12X10T (BLISTER PACK)		293.40	24.4
	THYROUP 75 (1X120 T) LUPIDIP 5 MG TAB 10X10 T	120 T 10 x 10 T	172.03 249.70	
	ETHIDE TABLETS 10 X 12T	10 X 10 T	1,775.40	
503537	LUPINIB 400 MG 3X10 TAB	3 X 10 T	5,981.70	1,993.9
	CHEMODOC 80MG	1 V	10,321.85	
	EPILIVE ER 750 10X10 T EPILIVE ER 500 10X10 T	10 x 10 T 10 x 10 T	1,827.80 1,276.50	
	CLAVIDUR 1.2 INJ	1 V	140.45	
415867	CEFANTRAL 1.00G IP(10X1V) W/O WFI		399.00	39.9
	PYZINA 500 12X10T	12 x 10 T	585.60	
	R-CIN 150 5X2X10C LUPIDIP 2.5 MG TAB 10X10 T	5x2x10 C 10 x 10 T	228.00 179.00	
510295	THYROUP 150MCG (1X120 T)	120 T	213.69	
	CEFANTRAL 0.50G IP(10X1V) W/O WFI		243.00	
	ETHIDE TABLETS 5X6T RECLAIM (1X28T)	5x6 T 28 tablets	443.85 14,686.51	
	LNZ 600 TAB 10X4T W/O MONO	10X4T	1,425.00	142.
509513	LUTRAZOLE TAB (10X5)	10x5 T	1,464.40	146.4
	CEFANTRAL 0.250G IP(10X1V) W/O	10x1 V	176.50	
* in457	CLOPITAB 10 X 2 X 15 TABS CIPROLUP-500: (20X10)	10 X 2 X 15 T 20X10T	1,995.00 849.00	
	CIFICEOF-300. 120X 101			42.4
502702	CIPROVA 500 MG (20X10)	20X10T	849.00	
502702 503772 502203	CIPROVA 500 MG (20X10) CORTILUP INJ	1 V	41.95	41.9
502702 503772 502203 500006	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10)	1 V 20X10T	41.95 849.00	41.9 42.4
502702 503772 502203 500006 503861	CIPROVA 500 MG (20X10) CORTILUP INJ	1 V	41.95	41.9 42.4 97.6
502702 503772 502203 500006 503861 500734 511779	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPILAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10)	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T	41.95 849.00 976.50 466.00 1,827.50	41.4 42.4 97.4 11.4 182.
502702 503772 502203 500006 503861 500734 511779 506601	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPILAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6	41.95 849.00 976.50 466.00 1,827.50 2,193.00	41.9 42.4 97.6 11.6 182.1
502702 503772 502203 500006 503861 500734 511779 506601 503746	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPILAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU)	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T	41.95 849.00 976.50 466.00 1,827.50 2,193.00 976.50	41.9 42.4 97.6 11.6 182.7 109.6
502702 503772 502203 500006 503861 500734 511779 506601 503746 508545	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPICAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10)	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6	41.95 849.00 976.50 466.00 1,827.50 2,193.00	41.9 42.4 97.6 11.6 182.7 109.6 97.6
502702 503772 502203 500006 503861 500734 511779 506601 503746 508545 512452 512227	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPICAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10) ONE CLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TAB. (20X1X6)	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T 10 x 10 T (10X1X10'S) 20X1X6	41.95 849.00 976.50 466.00 1,827.50 2,193.00 976.50 1,827.50 2,193.00	41.9 42.4 97.0 11.0 182.1 109.0 97.0 182.1 109.0
502702 503772 502203 500006 503861 500734 511779 506601 503746 508545 512452 512227 507683	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPICAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10) ONE CLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TAB. (20X1X6) LUPIPAN INJ	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T 10 x 10 T (10X1X10'S) 20X1X6 40 mg/vial	41.95 849.00 976.50 466.00 1,827.50 2,193.00 976.50 976.50 1,827.50 2,193.00 50.40	41.42.42.97.11.1.182.109.97.182.109.182.109.50.50.
502702 503772 502203 500006 503861 500734 511779 506601 503746 508545 512452 512227 507683 512468	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPICAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10) ONE CLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TAB. (20X1X6) LUPIPAN INJ XTRACLAV 625 TABLET (10X1X10'S)	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T 10 x 10 T (10X1X10'S) 20X1X6 40 mg/vial (10X1X10'S)	41.95 849.00 976.50 466.00 1,827.50 2,193.00 976.50 1,827.50 2,193.00	41.42.42.4 97.7 11.1 182.1 109.1 182.1 109.1 182.1 109.1 182.1 109.1 182.1 109.1 182
502702 503772 502203 500006 503861 500734 511779 506601 503746 508545 512452 512227 507683 512468 509821	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPICAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10) ONE CLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TAB. (20X1X6) LUPIPAN INJ XTRACLAV 625 TABLET (10X1X10'S) FLUCALUP 200 MG TABS (20X1X1)	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T 10 x 10 T (10X1X10'S) 20X1X6 40 mg/vial	41.95 849.00 976.50 466.00 1,827.50 2,193.00 976.50 976.50 1,827.50 2,193.00 50.40	41.1 42.2 97.1 1182. 109.9 97.1 182. 109.0 50.0 182.
502702 503772 502203 500006 503861 500734 511779 506601 503746 508545 512452 512227 507683 512468 509821 512676 502896	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPILAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10) ONE CLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TABLET (10X1X10'S) LUPIPAN INJ XTRACLAV 625 TABLET (10X1X10'S) FLUCALUP 200 MG TABS (20X1X1) E-CEF -200 (10X1X10) DEFENAC INJ 3 ML (100X3ML)	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T 10 x 10 T (10X1X10'S) 20X1X6 40 mg/vial (10X1X10'S) 20X1X1 (10X1X10'S) 100X3ML	41.95 849.00 976.50 466.00 1,827.50 2,193.00 976.50 1,827.50 2,193.00 50.40 1,827.50 348.00 976.50 505.00	41.9 42.4 42.4 97.1 11.6 109.0 97.1 182 109.0 182 17.4 97.6 5.0
502702 503772 502203 500006 503861 500734 511779 506601 503746 508545 512452 512227 507683 512468 509821 512676 502896	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPICAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10) ONE CLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TABLET (10X1X10'S) FLUCALUP 200 MG TABS (20X1X1) E-CEF -200 (10X1X10) DEFENAC INJ 3 ML (100X3ML) FLUCALUP 150 MG (20X1) WITH	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T 10 x 10 T (10X1X10'S) 20X1X6 40 mg/vial (10X1X10'S) 20X1X1 (10X1X10'S)	41.95 849.00 976.50 466.00 1,827.50 2,193.00 976.50 976.50 1,827.50 2,193.00 50.40 1,827.50 348.00	41.9 42.4 42.4 97.1 11.6 109.0 97.1 182 109.0 182 17.4 97.6 5.0
502702 503772 502203 500006 503861 500734 511779 506601 503746 508545 512452 512227 507683 512468	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPILAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10) ONE CLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TABLET (10X1X10'S) LUPIPAN INJ XTRACLAV 625 TABLET (10X1X10'S) FLUCALUP 200 MG TABS (20X1X1) E-CEF -200 (10X1X10) DEFENAC INJ 3 ML (100X3ML)	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T 10 x 10 T (10X1X10'S) 20X1X6 40 mg/vial (10X1X10'S) 20X1X1 (10X1X10'S) 100X3ML	41.95 849.00 976.50 466.00 1,827.50 2,193.00 976.50 1,827.50 2,193.00 50.40 1,827.50 348.00 976.50 505.00	41.9 42.4 97.6 11.0 182.1 109.0 97.6 182.1 109.0 50.4 17.7 97.6 5.6 12.0
502702 503772 5032203 500006 503861 500734 501779 506601 503746 503746 504545 512452 512227 507683 512452 512267 507683 512452 512267 507683 512468 5124888 512488 512488 512488 512488 512488 512488 512488 5124	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPICAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10) ONE CLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TABLET (10X1X10'S) FLUCALUP 200 MG TABS (20X1X1) E-CEF -200 (10X1X10) DEFENAC INJ 3 ML (100X3ML) FLUCALUP 150 MG (20X1) WITH MONO CARTON LUPICAT TABS (10X6X10'S) LUPICAR SUSPN 60 ML	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T 10 x 10 T 10 x 10 T (10X1X10'S) 20X1X6 40 mg/vial (10X1X10'S) 20X1X1 (10X1X10'S) 20X1X1 (10X1X10'S) 20X1X1 100X3ML 20X1X1 10X6X10'S 60 ML	41.95 849.00 976.50 466.00 1,827.50 976.50 976.50 1,827.50 2,193.00 50.40 1,827.50 348.00 976.50 241.00	41.9 42.4 42.4 97.6 11.4 109.6 97.6 182.1 109.6 109.6 17.4 17.4 12.6 18.8 18.8 18.8 19
502702 503772 5032203 500006 503861 500734 501779 506601 503746 503746 50457 5047683 512452 512227 507683 512452 512267 507683 512452 51227 507683 512452 51227 507683 512468 512468 51247 50340	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPICAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10) ONE CLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TABLET (10X1X10'S) THUCALUP 200 MG TABS (20X1X1) E-CEF -200 (10X1X10) DEFENAC INJ 3 ML (100X3ML) FLUCALUP 150 MG (20X1) WITH MONO CARTON LUPICAT TABS (10X6X10'S) LUPIPARA SUSPN 60 ML LUPIPARA SUSPN 60 ML	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T 10 x 10 T 10 x 10 T (10X1X10'S) 20X1X6 40 mg/vial (10X1X10'S) 20X1X1 (10X1X10'S) 20X1X1 (10X1X10'S) 100X3ML 20X1X1 10X6X10'S 60 ML 60 ML	41.95 849.00 976.50 466.00 1,827.50 976.50 976.50 1,827.50 2,193.00 50.40 1,827.50 348.00 976.50 241.00 1,128.00 22.15	41.9 41.9 42.4 42.4 42.4 42.4 43.4 44.4 45.4 46.4 46.4 46.4 46.4 46.4 46
502702 503772 5032203 500006 503861 500734 501779 506601 503746 503746 50457 5047683 512452 512227 507683 512452 512267 507683 512452 51227 507683 512452 51227 507683 512468 512468 51247 50340	CIPROVA 500 MG (20X10) CORTILUP INJ LUCIPRO 500(20*10) LUPICEFF - O 200 (10X10) LUPICAX TABS (20 X 2 X 10T) LUPICLAV 625 TABS (10X10) ONE CLAV 625 20X6 XIMECEFF 200 10X10 (ALU ALU) E-CEF -200 TABS (10X10) ONE CLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TABLET (10X1X10'S) XTRACLAV 625 TABLET (10X1X10'S) FLUCALUP 200 MG TABS (20X1X1) E-CEF -200 (10X1X10) DEFENAC INJ 3 ML (100X3ML) FLUCALUP 150 MG (20X1) WITH MONO CARTON LUPICAT TABS (10X6X10'S) LUPIPARA SUSPN 60 ML LUPIPARA FORTE 60 ML PREGNOT KIT (10X1X5)	1 V 20X10T 10 x 10 T 20X2X10 10 x 10 T 20X6 10 x 10 T 10 x 10 T 10 x 10 T (10X1X10'S) 20X1X6 40 mg/vial (10X1X10'S) 20X1X1 (10X1X10'S) 20X1X1 (10X1X10'S) 20X1X1 100X3ML 20X1X1 10X6X10'S 60 ML	41.95 849.00 976.50 466.00 1,827.50 976.50 976.50 1,827.50 2,193.00 50.40 1,827.50 348.00 976.50 241.00	41.9 42.4

For LUPIN LIMITED Place: Mumbai Subhash Talukdar **Date**: 23rd Jan, 2023 Vice President- Distribution

942.50

94.25

Place: New Delhi

Date : 23rd January, 2023

500216 CLAMYCIN 250 10X4 TAB



egd. Office : First Floor, Khivraj Complex 1, No. 480, Anna Salai, Nandanam, Chennai 600 035. Phone No.: 24313094 - 97 CIN No: L65191TN1989PLC017883 Email: investors@indbankonline.com Website: www.indbankonline.com

Statement of Un-Audited Financial Results for / upto the quarter ended 31.12.2022

S		Quarter ending	Year to date figures	Corresponding three months ended in the previous year				
IN	,	31/12/22	31/12/22	31/12/21				
		Un-Audited	Un-Audited	Un-Audited				
			Rs. lakhs					
1	Total Income From Operations	431.96	1203.47	545.92				
2	. Net Profit / (Loss) for the period (before tax, Exceptional and / or Extraordinary items)	226.28	404.94	318.04				
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items)	226.28	404.94	318.04				
4	. Net Profit / (Loss for the period after tax (after Exceptional and / or Extraordinary items)	174.78	296.05	299.37				
5	. Total Comprehensive income for the period [Comprising Profit / (Loss) for the period (after tax) and other Comprehensive income (after tax)]	172.20	287.86	299.37				
6	. Equity Share Capital	4437.82	4437.82	4437.82				
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year	2675.42						
8	. Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations) -							
	1. Basic	0.39	0.67	0.67				
	2. Diluted	0.39	0.67	0.67				
	Note: (1) The above financial results have been reviewed by the Audit Comm	nittee of Board and	approved by the Boar	d of Directors at their				

meeting held on 21.01.2023. (2) The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange Websites. NSE: www.nseindia.com, BSE:www.bseindia.com and our company's website www.indbankonline.com

Place: Chennai **V HARIBABU** Date: 21.01.2023 PRESIDENT & WHOLE TIME DIRECTOR

Ind Bank

Registered Office: 3rd Floor, Khivraj Complex 1, No. 480, Anna Salai, Nandanam, Chennai 600 035.
CIN No:L65922TN1991PLC020219 Email: indhouse@indbankhousing.com Website: www.indbankhousing.com Ph: 2432 9235

Statement of unaudited Einanaial Deputts for the Quarter anded 21 12 2020

	Statement of unaudited Financial Results for	tne Quarter e	naea 31.12.20	J22
SI.	Particulars	Three months ended	Year to date figures for the current period ended	Corresponding three months ended in the previous year
No.		31.12.2022	31.12.2022	31.12.2021
		Unaudited	Unaudited	Unaudited
			Rs. lakhs	
1.	Total Income	7.50	17.58	5.29
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(1.44)	(15.33)	(3.28)
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(1.44)	(15.33)	(3.28)
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	(1.44)	(15.33)	(3.28)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive income (after tax)]	(1.44)	(15.35)	(3.28)
6.	Equity Share Capital	1000.00	1000.00	1000.00
7.	Reserves (excluding Revaluation Reserves) as shown in the Audited Balance sheet of previous year	(12931.87)	(12931.87)	(12918.93)
8.	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations) - 1. Basic 2. Diluted	(0.01) (0.01)	(0.15) (0.15)	0.03 0.03

Note: The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange Websites. BSE: www.bseindia.com and our company website: www.indbankhousing.com

Place: Chennai V.HARIBABU Date: 21.01.2023 MANAGING DIRECTOR




MAHARASHTRA SEAMLESS LIMITED

(D.P. JINDAL GROUP COMPANY)

Registered Office: Pipe Nagar, Village Sukeli, BKG Road, NH-17, Taluka Roha, Distt. Raigad-402126 (Maharashtra) Tel. No. 02194 - 238511; E-mail: secretarial@mahaseam.com; Website www.jindal.com Corporate Office: Plot No. 30, Institutional Sector - 44, Gurugram - 122003 (Haryana)

Interim Corporate Office: Plot No.106, Institutional Sector-44, Gurugram-122 003 (Haryana); CIN: L99999MH1988PLC080545





EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2022

STANDAL ONE

(Rs. in Lakhs, except per share data)

CONSOLIDATED

SI.		STANDALONE							CONSOLIDATED							
	Particulars	Quarter Ended			Nine Mon	Nine Months Ended		Quarter Ended			Nine Mon	Year Ended				
		31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22			
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited			
1.	Total income from operations	1,11,463	1,14,808	94,679	3,32,031	2,36,419	3,55,609	1,33,855	1,41,421	1,13,940	4,08,713	2,78,130	4,20,029			
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	16,435	16,403	12,342	48,180	35,656	48,151	22,027	22,460	14,552	64,421	38,731	53,450			
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	16,435	16,403	12,342	48,180	35,656	48,151	21,260	21,746	13,637	62,269	36,506	50,523			
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	12,367	12,305	9,141	36,079	28,706	38,045	17,192	17,659	10,423	50,179	29,543	40,404			
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	12,407	12,345	9,185	36,199	28,844	38,205	17,284	17,845	10,463	50,564	30,033	42,381			
6.	Equity Share Capital (Face Value of Rs. 5/- each)	6,700	3,350	3,350	6,700	3,350	3,350	6,700	3,350	3,350	6,700	3,350	3,350			
7.	Other Equity						3,56,870						3,66,311			
8.	Earning per Share (EPS) - Basic/Diluted Earning Per Share Not Annualised (Rs.)	9.23	9.18	6.82	26.92	21.42	28.39	12.82	13.18	7.07	37.43	21.00	28.37			
Note	es:															

Place: New Delhi

Date: 23rd January, 2023

- The above is an extract of the detailed format of Financial Results for the quarter & nine months ended 31st December 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full format of financial results for the quarter & nine months ended 31st December, 2022 are available on the website(s) of Stock Exchanges i.e. www.nseindia.com and www.bseindia.com and on the website of the Company i.e. www.jindal.com.
- 2. The Company has allotted 66,999,626 Equity shares of Rs. 5 each as bonus shares on 5th December 2022 to shareholders whose name appeared in the register of members and the beneficial owners as provided by Depositories as on the record date i.e. 28th November 2022 in the ratio of 1:1 by capitalization of reserves. Accordingly, the earnings per share (basic and diluted) for the current quarter and previous periods have been calculated taking impact of bonus shares.
- 3. During the quarter the Company (MSL) had gone for maintenance shutdown of hot mill facility of one seamless pipe manufacturing mill at Nagothane for 4 weeks leading to lower production and dispatches. During the quarter total seamless pipes produced by the Company was 75,566 MT (Q2 FY23 88,956 MT) and total dispatches were 78,226 MT (Q2 FY23 90,362 MT).

For MAHARASHTRA SEAMLESS LIMITED



SAKET JINDAL Managing Director DIN:00405736

JINDAL DRILLING AND INDUSTRIES LIMITED

(D.P. JINDAL GROUP COMPANY)

Registered Office: Pipe Nagar, Village Sukeli, N.H. 17, B.K.G.Road Taluka Roha, Distt: Raigad-402126, Maharashtra (India) $Tel:\ 02194-238511-12,\ Fax:\ 02194-238511,\ Web:\ www.jindal.com,\ E-mail:\ secretarial@jindaldrilling.in$ Corporate Office: Plot No. 30, Institutional Sector-44, Gurugram - 122003 (Haryana)

Interim Corporate Office: Plot No.106, Institutional Sector-44, Gurugram-122 003 (Haryana), CIN: L27201MH1983PLC233813 EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2022

(Rs. in Lakhs, except per share data)

		STANDALONE							CONSOLIDATED							
SI. No.	Particulars	Quarter Ended			Nine Months Ended Year Ended			Quarter Ended			Nine Mon	Year Ended				
110.		31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22			
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited			
1.	Total income from operations including other income	14,560	15,558	12,695	45,110	33,921	45,184	14,560	15,558	12,695	45,110	33,921	45,184			
2.	Net profit / (loss) for the period (before tax, Exceptional and/or Extraordinary items)	3,462	4,799	2,661	12,672	5,528	8,679	3,462	4,799	2,661	12,672	5,528	8,679			
3.	Net profit / (loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,462	4,799	2,661	12,672	5,528	8,679	3,395	4,398	3,721	11,953	5,925	8,658			
4.	Net profit / (loss) for the period after tax (after Exceptional and/or Extraordinary items but before Other Comprehensive Income)	2,554	3,575	2,383	9,389	4,130	6,468	2,487	3,174	3,443	8,670	4,527	6,447			
5.	Total comprehensive income for the period [comprising profit /(loss) for the period after tax and other comprehensive income (after tax)]	2,590	3,276	2,159	8,749	4,088	6,375	3,109	3,877	3,070	10,962	4,809	7,399			
6.	Equity Share Capital (Face value of Rs. 5 each)	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449			
7.	Other equity						94,489						1,17,965			
8.	Earning per Share (of Rs. 5 each) - Basic/Diluted Earning Per Share Not Annualised (Rs.)	8.81	12.34	8.22	32.40	14.25	22.32	8.58	10.95	11.88	29.92	15.62	22.25			

1. The above is an extract of the detailed format of Financial Results for the quarter & nine months ended 31st December 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full format of financial results for the quarter & nine months ended 31st December, 2022 are available on the website(s) of Stock Exchanges i.e. www.nseindia.com and www.bseindia.com and on the website of the Company i.e. www.jindal.com.



for JINDAL DRILLING AND INDUSTRIES LIMITED

RAGHAV JINDAL Managing Director DIN: 00405984

अवैध रेती उपसाविरोधातली कारवाई थंडावली?

ठाणे / प्रतिनिधी

जिल्ह्यात रेती लिलाव गेली काही वर्षे बंद असल्याने रेती माफिया फोफावले आहेत. चोरट्या रेती व्यवसायात मोठ्या प्रमाणात वाढ झाल्याचे आरोप होत आहेत. गेल्या दोन वर्षांत काही ठिकाणी झालेल्या रेती लिलावामुळे अधिकृतपणे रेती उत्खनन सुरू होते. मात्र त्यांनतर रेती लिलावाला ठेकेदार मिळत नसल्यामुळे रेती लिलाव बंद करण्यात आले आहेत, ते अद्यापपर्यंत बंदच आहे. दुसरीकडे रेती चोरट्यांच्या विरोधातील कारवाई थंडावली असल्याने रेती माफियांना सुगीचे दिवस आल्याचे म्हटले जात आहे.

याप्रकरणी २०१६-१७ या वर्षात ११९ गुन्हे, २०१७-१८ या वर्षात ३७ गुन्हे, तर चालू वर्षात अवधे ३ गुन्हे दाखल झाले असल्याचे उघडकीस आले आहे. २०१६-१७ साली तत्कालीन जिल्हाधिकारी डॉ. अश्विनी जोशी यांनी रेती माफियांच्या विरोधात विशेष मोहीम उघडल्याने अवैध रेती व्यवसायाचे कंबरडे मोडले होते. त्यांनी महसूल, रेशनिंग विभागाचे अधिकारी आणि पोलीस कर्मचाऱ्यांचे सुमारे १२५ जणांचे पथक तयार केले होते. या पथकाने मुंब्रा रेती बंदर,

रेती चोरीचा व्यवसाय तेजीत: ठाण्याला लाभलेला खाडीकिनारा आणि याच किनाऱ्यावर राजरोसपणे होणारे रेती उत्खनन हे पूर्वी रेती व्यवसायातील मजुरांच्या उदरिनर्वाहाचे साधन होते. मात्र आज तो व्यापार झाला आहे. मूळ मजूर गायब झाले आहेत आणि रेती माफियांनी त्याची जागा घेतली आहे. खाडीकिनाराच्या रेती उत्खनाने भूत्स्खलनाचा घोका निर्माण झाल्याने शासनाने बहुतांशी ठिकाणी रेती उत्खननाचे परवाने बंद केले. मात्र मुंबा स्टेशन, चुआ ब्रीज आणि कशेळी येथे अवैध पद्धतीने रेतीचा चोरटा व्यापार सुरू असल्याचे सांगण्यात येत आहे.

■ २०१६-१७ साली ११९ गुन्हे ■ २०१७-१८ साली ३७ गुन्हे

गायमुख, रेती बंदर, नागला खाडी, कल्याण, मोठा गाव ठाकुर्ली, वेहळे आणि अंजूरफाटा येथील रेती

■ चालू वर्षात अवधे ३ गुन्हे दाखल

उपसा करणाऱ्यांवर कारवाई केली होती. काल्हेर व कशेळी येथे छापा टाकून सुमारे १ कोटी १३ लाख ४२ हजार रुपये किमतीहून अधिकचा रेतीसाठा जप्त करण्यात आला होता. तर यामध्ये २२ क्रेन, तीन ट्रक, डंपर, सक्शन पंप, लाकडी बोटी आदी जप्त करण्यात आल्या होत्या, त्याची किंमत सुमारे १० कोटी होती. अशा प्रकारे २०१६-१७ या वर्षात रेतीचोरांच्या विरोधात एकूण ११९ गुन्हे दाखल झाले होते. मात्र त्यानंतर रेती चोरांच्या विरोधातील कारवाया काहीशा थंडावल्या असल्याचे चित्र पहावयास मिळाले.

२०१७-१८ या वर्षात रेती चोरांच्या विरोधात अवघे ३७ गुन्हे दाखल करण्यात आले होते, तर २०१९-२० या वर्षात फक्त १४ गुन्हे दाखल करण्यात आले आहेत. २०१८-१९ या वर्षात १२ कोटी २० लाख रुपयांच्या दंड वसुलीचे टार्गेट देण्यात आले होते, मात्र एप्रिल २०१८ ते डिसेंबर २०१८ या आठ महिन्यांत १,३१६ ट्रकवर कारवाई करून ३ कोटी ५६ लाख ६८ हजार रुपयांचा दंड वसूल करण्यात आला होता. २०१९-२० साली तर सक्शन पंप ३०, २६ बोटी, १० क्रेन २४०० ब्रास रेती जप्त करून ७ जणांच्या विरोधात गुन्हे दाखल करण्यात आले होते.

हेल्थ टुरिझमच्या माध्यमातून अर्थव्यवस्थेला चालना

उपमुख्यमंत्री देवेंद्र फडणवीस यांच्या हस्ते भारती विद्यापीट मेडिकव्हर रुग्णालयाचे उद्घाटन

नवी मुंबई : भारती विद्यापीठ मेडिकव्हर रुग्णालयातर्फें नवी मुंबईत नवीन रुग्णालय सुरू करण्यात आले आहे. या रुग्णालयाचे उद्घाटन महाराष्ट्राचे उपमुख्यमंत्री देवेंद्र फडणवीस यांच्या हस्ते करण्यात आले. यावेळी गुणवत्तापूर्ण शिक्षण भारती विद्यापीठाची विशेषता असून, हेल्थकेअर क्षेत्रातही भारती विद्यापीठाची वाटचाल उत्कृष्टपणे सुरू आहे, असे गौरवोद्गार उपमुख्यमंत्री देवेंद्र फडणवीस यांनी खारघर येथे काढले.

भारती विद्यापीठाच्या खारघर, सेक्टर-१० (कोपरा) येथील अत्याधुनिक अशा मेडिकव्हर हॉस्पिटलच्या उद्घाटन सोहळ्यात अध्यक्ष स्थानाहून उपमुख्यमंत्री फडणवीस बोलत होते. देवेंद्र फडणवीस म्हणाले की, भारती विद्यापीठाने विविध उपक्रमाच्या माध्यमातून नेहमी मानव संसाधन निर्माण केले आहे. गुणवत्तापूर्ण शिक्षण उपलब्ध करून देणे ही भारतीय विद्यापीठाची खासियत आहे. भारती विद्यापीठ आणि मेडिकव्हरच्या संयुक्त विद्यामाने एक नवीन रुग्णालय सुरू करण्यात



आले आहे. कोरोना काळानंतर जगभरातील प्रगत देशांनाही आरोग्य क्षेत्रात असलेल्या उणिवा लक्षात आल्या आहेत. त्यामुळे देशासह जगभरात वैद्यकीय क्षेत्रात मोठ्या प्रमाणात आपल्याला काम करण्याची गरज असल्याचे लक्षात आले आहे. दोन-तीन दशकांपासून आरोग्य क्षेत्रात मोठ्या प्रमाणात बदल झालेला दिसून येत आहे. यामुळे हेल्थ केअर क्षेत्र हेल्थ दुरिझमच्या दिशेने वाटचाल करताना दिसून येत आहे. या हेल्थ दुरिझमच्या माध्यमातून अर्थव्यवस्थेला चालना मिळेल, असे फडणवीस यांनी म्हटले आहे.

डॉ. विश्वजीत कदम म्हणाले की, भारती विद्यापीठाची स्थापना डॉ. पतंगराव कदम यांनी बहुजन समाजातील मुलांच्या शिक्षणासाठी केली. भारती विद्यापीठ आणि मेडिकव्हर ग्रामीण भागातील लोकांना वैद्यकीय सेवा पुरविण्यासाठी काम करत आहे.

पृथ्वीराज चव्हाण म्हणाले की, भारती विद्यापीठ आणि मेडिकव्हरच्या संयुक्त विद्यामाने हे रुग्णालय सुरू करण्यात आले आहे. मेडिकव्हर ही संस्था देशभरात वैद्यकीय क्षेत्रात काम करत आहे. युरोपीयन समुहाशी भागीदारी झाल्यामुळे युरोप खंडातील वैद्यकीय व्यावसायी मानक भारतात यायला मदत होईल. महाराष्ट्रातील सरकारी रुग्णालयात रुग्णांच्या वाढत्या संख्येच्या तुलनेत डॉक्टरांची संख्या अपरी पडत आहे.



महाप्रित, आय.आय.टी. बॉम्बे यांच्यात सामंजस्य करार

मुंबई : महात्मा फुले निवनीकरणीय ऊर्जा व पायाभूत प्रौद्योगिकी मर्यादित (महाप्रित) व आय.आय.टी. बॉम्बे यांच्यात कार्बन कॅप्चरिंग व ग्रीन हायड्रोजन तंत्रज्ञानाबाबत संयुक्त प्रकल्प राबविण्याच्या दृष्टिकोनातून सामंजस्य करार करण्यात आला.

या कराराच्यावेळी महाप्रितचे अध्यक्ष व व्यवस्थापकीय संचालक बिपीन श्रीमाळी (भा.प्र.से.), महाप्रितचे मुख्य महाव्यवस्थापक शरणप्पा कोल्लूर, दूरदृश्य प्रणालीव्दारे उपस्थित होते. आय.आय.टी. बॉम्बेचे अधिष्ठाता डॉ. मिलंद अत्रे, नॅशनल सेंटर फॉर एक्सलन्स इन कार्बन कॅप्चरचे समन्वयक डॉ. विक्रम विशाल, सहप्राध्यापक डॉ. अर्णब दत्ता, महाप्रितचे संचालक (संचलन)

वि. ना. काळम पाटील, कार्यकारी संचालक (संचलन) सुनील पोटे, कार्यकारी संचालक (प्रशासन) धामणकर उपस्थित होते. या सामंजस्य कराराव्दारे आयआयटी बॉम्बे येथील विकसित करण्यात आलेल्या कार्बन कॅप्चर व किफायतशीर ग्रीन तंत्रज्ञानावर आधारित प्रकल्प संयुक्तपणे राबविण्यात येणार आहे. सद्यस्थितीत तापमानवाढीच्या समस्येवर या प्रकल्पामुळे मोठ्या प्रमाणात जनजागृती निर्माण नवनवीन तंत्रज्ञान विकसित ही झाल्यामुळे समस्या सोडविण्यासाठी मोठ्या प्रमाणावर मदत होणार आहे.

महावितरणच्या पथकाला मारहाण करणाऱ्याविरुद्ध गुन्हा दाखल

डोंबिवली: थकबाकीपोटी खंडित केलेला वीजपुरवठा पुन्हा सुरू असल्याचे महावितरणच्या पथकाला आढळले. यावर कारवाई करणाऱ्या पथकातील बाह्यस्त्रोत कर्मचाऱ्याला मारहाण केल्याची घटना डोंबिवलीतील आजदे गावात घडली आहे, तर पथकातील महिला विद्युत सहाय्यकालाही शिवीगाळ करण्यात आली. याप्रकरणी मानपाडा पोलीस ठाण्यात सरकारी कामात अडथळा व मारहाणीचा गुन्हा दाखल करण्यात आला आहे.

मिळालेल्या महितीनुसार, नागेश धर्मदास गमरे (समर्थ दर्शन बिल्डिंग, बी-४०३, हनुमान मंदिराजवळ, आजदे) असे गुन्हा दाखल झालेल्याचे नाव आहे. महिला विद्युत सहाय्यक विजया भुयारकर या बाह्यस्त्रोत कर्मचारी आकाश गिरी यांच्यासह आजदे परिसरात तपासणीचे काम करत होत्या. रघुनाथ बाळकु आवटे या ग्राहकाचा वीजपुरवठा थकबाकीपोटी खंडित करण्यात आला होता. मात्र, याठिकाणी परस्पर केबल जोडून वीजपुरवठा सुरू असल्याचे आढळून आले. त्यानुसार कारवाई करताना भाडेकरू असणाऱ्या गमरे याने बाह्यस्त्रोत कर्मचारी आकाश गिरी यांना मारहाण केली व महिला विद्युत सहाय्यक भुयारकर यांना शिवीगाळ केली. भुयारकर यांच्या फिर्यादीवरून मानपाडा पोलिसांनी गमरेविरुद्ध गुन्हा दाखल केला आहे.

टाण्यातून ४५१ किलो प्लास्टिक जप्त

ठाणे : ठाणे महापालिकेच्या माध्यमातून संपूर्ण महापालिका कार्यक्षेत्रात प्लास्टिक बंदीवरील कारवाई नियिमतपणे सुरू असून, सोमवारी घनकचरा व्यवस्थापन विभागामार्फत वागळे इस्टेट, उथळसर, कळवा व दिवा प्रभाग समिती कार्यक्षेत्रात कारवाई करण्यात आली. या तिन्ही विभागांतर्गत करण्यात आलेल्या कारवाईत एकूण ४५१ किलो प्लास्टिक जप्त करण्यात आले असून यापोटी एकुण ११५०० रुपये इतका दंड वसूल करण्यात आला. वागळे प्रभाग समिती अंतर्गत प्लास्टिक बंदी अभियान राबविण्यात आले. या विभागात एकुण २३ आस्थापनांची तपासणी करण्यात आली असून एकूण ३ किलो प्लास्टिक जप्त करण्यात आले. त्यांचकडून ५,००० रुपये इतका दंड वसूल करण्यात आला आहे. उथळसर प्रभाग समिती अंतर्गत गोकुळ दास वाडी खोपट

येथील एका प्लास्टिक गोडावून



मध्ये ४५० किलो प्लास्टिक जप्त करण्यात आले, असून ५००० रुपये इतका दंड वसूल करण्यात

कळवा प्रभाग समिती क्षेत्रात एकूण ८ आस्थापनांना भेटी देऊन १ किलो प्लास्टिक जप्त करण्यात आले असून त्यापोटी एकूण दंड १५०० र. वसूल करण्यात आला. सदरची कारवाई आरोग्य अधिकारी डॉ. बालाजी हळदेकर यांच्या मार्गदर्शनानुसार मुख्य स्वच्छता निरीक्षक जयंत पटनाईक, रायमन दांडेकर, उपमुख्य स्वच्छता यांच्या देखरेखीखाली करण्यात आली.

MAHARASHTRA SEAMLESS LIMITED

(D.P. JINDAL GROUP COMPANY)

Registered Office: Pipe Nagar, Village Sukeli, BKG Road, NH-17, Taluka Roha, Distt. Raigad-402126 (Maharashtra)
Tel. No. 02194 - 238511; E-mail: secretarial@mahaseam.com; Website www.jindal.com
Corporate Office: Plot No. 30, Institutional Sector - 44, Gurugram - 122003 (Haryana)
Interim Corporate Office: Plot No.106, Institutional Sector-44, Gurugram-122 003 (Haryana); CIN: L99999MH1988PLC080545





EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2022

(Rs. in Lakhs, except per share data)

				STAND	ALONE			CONSOLIDATED						
SI.	Particulars	Q	Quarter Ended			Nine Months Ended		Quarter Ended		∍d	Nine Mon	nths Ended	Year Ended	
		31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1.	Total income from operations	1,11,463	1,14,808	94,679	3,32,031	2,36,419	3,55,609	1,33,855	1,41,421	1,13,940	4,08,713	2,78,130	4,20,029	
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	16,435	16,403	12,342	48,180	35,656	48,151	22,027	22,460	14,552	64,421	38,731	53,450	
3.	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	16,435	16,403	12,342	48,180	35,656	48,151	21,260	21,746	13,637	62,269	36,506	50,523	
4.	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	12,367	12,305	9,141	36,079	28,706	38,045	17,192	17,659	10,423	50,179	29,543	40,404	
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	12,407	12,345	9,185	36,199	28,844	38,205	17,284	17,845	10,463	50,564	30,033	42,381	
6.	Equity Share Capital (Face Value of Rs. 5/- each)	6,700	3,350	3,350	6,700	3,350	3,350	6,700	3,350	3,350	6,700	3,350	3,350	
7.	Other Equity						3,56,870						3,66,311	
8.	Earning per Share (EPS) - Basic/Diluted Earning Per Share Not Annualised (Rs.)	9.23	9.18	6.82	26.92	21.42	28.39	12.82	13.18	7.07	37.43	21.00	28.37	

Notes:

- 1. The above is an extract of the detailed format of Financial Results for the quarter & nine months ended 31st December 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full format of financial results for the quarter & nine months ended 31st December, 2022 are available on the website(s) of Stock Exchanges i.e. www.nseindia.com and www.bseindia.com and on the website of the Company i.e. www.jindal.com.
- 2. The Company has allotted 66,999,626 Equity shares of Rs. 5 each as bonus shares on 5th December 2022 to shareholders whose name appeared in the register of members and the beneficial owners as provided by Depositories as on the record date i.e. 28th November 2022 in the ratio of 1:1 by capitalization of reserves. Accordingly, the earnings per share (basic and diluted) for the current quarter and previous periods have been calculated taking impact of bonus shares.
- 3. During the quarter the Company (MSL) had gone for maintenance shutdown of hot mill facility of one seamless pipe manufacturing mill at Nagothane for 4 weeks leading to lower production and dispatches. During the quarter total seamless pipes produced by the Company was 75,566 MT (Q2 FY23 88,956 MT) and total dispatches were 78,226 MT (Q2 FY23 90,362 MT).

For MAHARASHTRA SEAMLESS LIMITED

Place: New Delhi Date: 23rd January, 2023 JINDAL GROUP

SAKET JINDAL Managing Director DIN:00405736

JINDAL DRILLING AND INDUSTRIES LIMITED

(D.P. JINDAL GROUP COMPANY)

Registered Office: Pipe Nagar, Village Sukeli, N.H. 17, B.K.G.Road Taluka Roha, Distt: Raigad-402126, Maharashtra (India)
Tel: 02194-238511-12, Fax: 02194-238511, Web: www.jindal.com, E-mail: secretarial@jindaldrilling.in
Corporate Office: Plot No. 30, Institutional Sector-44, Gurugram - 122003 (Haryana)
Interim Corporate Office: Plot No.106, Institutional Sector-44, Gurugram-122 003 (Haryana), CIN: L27201MH1983PLC233813

EXTRACT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2022

(Rs. in Lakhs, except per share data)

	!			STAND	DALONE			CONSOLIDATED							
SI. No.	Particulars	G	Quarter Ended			Nine Months Ended		C	Quarter Ende	ed	Nine Mon	nths Ended	Year Ended		
		31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22	31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22		
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited		
1.	Total income from operations including other income	14,560	15,558	12,695	45,110	33,921	45,184	14,560	15,558	12,695	45,110	33,921	45,184		
2.	Net profit / (loss) for the period (before tax, Exceptional and/or Extraordinary items)	3,462	4,799	2,661	12,672	5,528	8,679	3,462	4,799	2,661	12,672	5,528	8,679		
3.	Net profit / (loss) for the period before tax (after Exceptional and/or Extraordinary items)	3,462	4,799	2,661	12,672	5,528	8,679	3,395	4,398	3,721	11,953	5,925	8,658		
4.	Net profit / (loss) for the period after tax (after Exceptional and/or Extraordinary items but before Other Comprehensive Income)	2,554	3,575	2,383	9,389	4,130	6,468	2,487	3,174	3,443	8,670	4,527	6,447		
5.	Total comprehensive income for the period [comprising profit /(loss) for the period after tax and other comprehensive income (after tax)]	2,590	3,276	2,159	8,749	4,088	6,375	3,109	3,877	3,070	10,962	4,809	7,399		
6.	Equity Share Capital (Face value of Rs. 5 each)	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449	1,449		
7.	Other equity						94,489						1,17,965		
8.	Earning per Share (of Rs. 5 each) - Basic/Diluted Earning Per Share Not Annualised (Rs.)	8.81	12.34	8.22	32.40	14.25	22.32	8.58	10.95	11.88	29.92	15.62	22.25		

1. The above is an extract of the detailed format of Financial Results for the quarter & nine months ended 31st December 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full format of financial results for the quarter & nine months ended 31st December, 2022 are available on the website(s) of Stock Exchanges i.e. www.nseindia.com and www.bseindia.com and on the website of the Company i.e. www.jindal.com.

for JINDAL DRILLING AND INDUSTRIES LIMITED

RAGHAV JINDAL Managing Director DIN: 00405984

